Spring Research Update Meeting 2025
Our 2025 Spring Research Update Meeting will take place at BMA House, home of the British Medical Association, in Tavistock Square, London on 24 March where we invite guests to an inspiring agenda of some of the most up to date news of our funded...
Learn more
An overview of drug development for Parkinson’s
A recently published research report conducted by Parkinson’s research advocates and Cure Parkinson’s presents an encouraging overview of pipeline agents being clinically tested for Parkinson’s.
Dr Richard Wyse co-edits prestigious Cochrane Report
Cure Parkinson’s is honoured that our Director of Research, Dr Richard Wyse is co-editor of a new Cochrane Report titled ‘GLP‐1 receptor agonists for Parkinson’s disease’.
Further evidence of neuroprotection of simvastatin in Parkinson’s
Foundation, researchers have concluded that the elevated risk of Parkinson’s disease in patients with type ll diabetes might be mitigated depending on the type of drugs prescribed to treat this type of diabetes.
The liraglutide trial for people with Parkinson’s
This clinical trial will test the efficacy and safety of the diabetes drug liraglutide (a GLP-1 agonist) in people with Parkinson’s. The trial is taking place at the Cedars-Sinai Medical Center, Los Angeles, U.S. and was selected by the International Linked Clinical Trials committee; and is co-funded…
Blood plasma infusions for Parkinson’s
Blood plasma may have beneficial effects in neurodegenerative conditions, including Parkinson’s.